Therapies for active rheumatoid arthritis after methotrexate failure. - Wikidata - awgldk - TriplyDB

Therapies for active rheumatoid arthritis after methotrexate failure.

Therapies for active rheumatoid arthritis after methotrexate failure.

http://www.wikidata.org/entity/Q41925478

about

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis Folic Acid Supplementation for Rheumatoid Arthritis Patients on Methotrexate: The Good Gets Better Secukinumab for rheumatology: development and its potential place in therapy Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis Biologicals in rheumatoid arthritis: current and future EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Combination therapy with biologic agents in rheumatic diseases: current and future prospects Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study.Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches Differential immunomodulatory effects by Tripterygium wilfordii Hook f-derived refined extract PG27 and its purified component PG490 (triptolide) in human peripheral blood T cells: potential therapeutics for arthritis and possible mechanisms explain 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Can the painDETECT Questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for the Frederiksberg hospital's Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.Selection bias in rheumatic disease research.Effects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes.Early start and stop of biologics: has the time come?Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter.Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.APLAR rheumatoid arthritis treatment recommendations.Serum survivin predicts responses to treatment in active rheumatoid arthritis: a post hoc analysis from the SWEFOT trial.Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway.Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry.cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis.Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.Making smart investment decisions in clinical research Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region.Doubly blind: a systematic review of gender in randomised controlled trials.Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4+ T cells Current Practice Patterns and Educational Needs of Rheumatologists Who Manage Patients with Rheumatoid Arthritis.

P2860

Q24185797-C2BDDF65-9292-4BEB-B3EF-FFD0EEA954A3 Q24200922-6EAFE7B1-EA3C-4F65-A7AB-7655F4619097 Q26738523-5B4CACA4-98FB-4EEA-9E6A-CF33656C6EFA Q26751187-37E4537F-1512-481A-B7B6-00D9DAE78B35 Q26780316-F9CA33DE-D749-4C5F-8F80-451B87486AA1 Q26859134-65B414FC-8C15-45E8-B66D-0DF5A513C477 Q28066250-31126AE7-683E-44C3-B998-1F4FDCD5DE70 Q28543128-C11355A2-F90B-4DBB-9AD7-0075508A2F4D Q28652859-53A07259-2574-4D7D-BD43-3166EEF0DBAE Q30234528-3F389CF4-C47A-429D-8F7A-3457AE80EF8F Q30235341-DFECA31F-7FAB-44D4-8749-0949E901B245 Q30812918-6503A890-ADA1-4C5A-B71F-F48B3154DC27 Q30882161-8A9256EC-E4EC-4788-AB27-D8CB39730EFB Q34354935-8602C5BC-14D9-4359-BE38-0381BD004E3D Q34411088-30B68E58-9DDA-4FAE-956E-E9DA37820F61 Q34434750-B9E01FB7-0348-4D3B-B708-0DD2872A7281 Q34462745-371A6AA3-B6E6-4878-B6FE-1848F01AE4C2 Q34500921-BBC797E2-439C-4B86-9B5F-D1A7FCD18E02 Q34573121-A7BAE6D6-8F33-40E6-996E-7B538756DF6C Q34604619-F21BEFF7-DFFC-47C8-A014-1242EFE98677 Q34662693-BB8EAC0E-AF40-46FA-9113-8C62E8E72DE5 Q35064975-34E94545-DB07-44C2-ADDE-1A4E90CEBB21 Q35087279-9FB4EBB6-D425-4600-AED8-03544BBA0A14 Q35174817-57D5B91D-EBC6-49C1-8CB0-212114BFCFC7 Q35554857-1BA83B80-9E88-4BB7-947B-AE4E0CD5DC93 Q35605415-63D3EF0E-75C3-43CD-9FD4-E5B3A33860DB Q35762912-2D8BE5F0-FEA4-4FAE-8697-682C435874AC Q35792901-56A8BC88-6283-4307-BF27-5A6EC32BDC13 Q35797434-F71BCD77-D0BB-49AE-BC6E-4755A6A9EE05 Q35974381-56CBD3AC-7166-48C3-A5D1-FCBAD4B66D41 Q36098311-676D1383-2463-4486-9BC4-762B042D13C5 Q36174658-9DB48C5A-F68B-4B70-B60C-2E21DF29F724 Q36195284-A379795F-011B-498E-9DC2-C38745129835 Q36300479-FDAAF33F-D1FA-4CAC-9C19-08FA81866E38 Q36409914-AB9B4CA1-655D-4080-9680-EFE01F638CE9 Q36485495-502864C4-9DDC-4330-9135-651A35BBD6EF Q36658514-F9B38A27-12D2-4F70-B912-A2157C6A9D51 Q36805845-712E78A2-B1D0-48CD-A5FD-DA8A5EC95768 Q36939870-E24A0E0D-B284-4579-BC27-113C4A462D02 Q36942985-89EF9940-E149-4323-94B4-DDA8C34A45E3

P2860

Therapies for active rheumatoid arthritis after methotrexate failure.

http://www.wikidata.org/entity/Q41925478

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Therapies for active rheumatoid arthritis after methotrexate failure.

@en

type

label

Therapies for active rheumatoid arthritis after methotrexate failure.

@en

prefLabel

Therapies for active rheumatoid arthritis after methotrexate failure.

@en

P1433

Q41925478-9CD36D04-683A-49D0-A8EF-5F02D6ED9659

P1476

Q41925478-1BAFA6F3-5541-4C1A-AA08-F1F6EC580843

P2093

Q41925478-12C306DF-C6AE-4AF7-8144-0242350A5FAF

Q41925478-152E94C1-EBDB-4886-BF88-1E8F6A08EADF

Q41925478-24447F1C-934E-4C3D-84BB-FCAF0E774367

Q41925478-6348A0C0-DCFC-4719-A7AD-43B31C5F01FE

Q41925478-7107B00C-216F-4D10-ACE5-4CEB7532AFA4

Q41925478-7C8BDB4F-24F7-4760-A71C-A40FE07D8947

Q41925478-85A1B729-75D1-4258-B829-76F239C5194A

Q41925478-8DC8EE59-3BE3-4F98-9BE8-825CFFAB3967

Q41925478-9B727F27-25F9-4272-8B6B-4F93368A6CCE

Q41925478-A07C64BC-F47F-455B-A54D-48E2A368FA6D

P304

Q41925478-813A232E-40F5-45B0-A728-84E41A633A90

P31

Q41925478-EB61A941-A620-4F23-92AD-99A0ED5D27AC

P356

Q41925478-ECA20DC8-FCE4-425E-9F79-AEB0230F27F1

P407

Q41925478-2FE13181-C6B1-4016-97EE-26A42DAF1785

P433

Q41925478-BB9073F7-5E2A-4680-AE7F-FFB348F25162

P478

Q41925478-8808AA0E-3BD5-48DF-AC9B-0A73993520F6

P577

Q41925478-7543C48E-9802-49FF-A615-A5722E850E73

P698

Q41925478-572B978C-C57C-431E-A27F-568CBFED68B3

P356

P1433

The New England Journal of Medicine

P1476

Therapies for active rheumatoid arthritis after methotrexate failure.

@en

P2093

Amy C Cannella

http://www.w3.org/2001/XMLSchema#string

Aslam H Anis

http://www.w3.org/2001/XMLSchema#string

CSP 551 RACAT Investigators

http://www.w3.org/2001/XMLSchema#string

Ciaran S Phibbs

http://www.w3.org/2001/XMLSchema#string

Edward Keystone

http://www.w3.org/2001/XMLSchema#string

Gary Kunkel

http://www.w3.org/2001/XMLSchema#string

James R O'Dell

http://www.w3.org/2001/XMLSchema#string

Mary Brophy

http://www.w3.org/2001/XMLSchema#string

Robert A Lew

http://www.w3.org/2001/XMLSchema#string

Sarah Leatherman

http://www.w3.org/2001/XMLSchema#string

P304

307-318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1303006

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

369

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23755969

http://www.w3.org/2001/XMLSchema#string